NYSE:CBM - Cambrex Stock Price, Price Target & More

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.50 by $0.22. The biotechnology company had revenue of $141.10 million for the quarter, compared to analysts' expectations of $104.44 million. Cambrex had a net margin of 18.69% and a return on equity of 21.00%. The company's quarterly revenue was up 34.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Cambrex.

Cambrex issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $2.80 to $3.03 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.90.

3 Wall Street analysts have issued 1 year target prices for Cambrex's shares. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's stock price to reach $60.00 in the next twelve months. View Analyst Ratings for Cambrex.

Some companies that are related to Cambrex include Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH) and Array Biopharma (ARRY).

News articles about CBM stock have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cambrex earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Cambrex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.90%), Dimensional Fund Advisors LP (4.27%), Boston Partners (2.06%), Northern Trust Corp (1.76%), Fiera Capital Corp (1.32%) and Neumeier Poma Investment Counsel LLC (1.19%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Penn Capital Management Co. Inc., RMB Capital Management LLC, New York State Common Retirement Fund, Boston Partners, Nuveen Asset Management LLC, Comerica Bank and JW Asset Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

CBM stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Heartland Advisors Inc., Sei Investments Co., GW&K Investment Management LLC, BlackRock Inc., Carillon Tower Advisers Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $46.55.

Cambrex has a market capitalization of $1.54 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]